Table 1.
Patient characteristics.
| Characteristic | Total n = 50 |
|---|---|
| Age at diagnosis | |
| Median (min, max) | 60 (38–84) |
| Histological subtype (n = 50) | n (%) |
| Serous | 45 (90.0) |
| Clear cell | 3 (6.0) |
| Endometrioid | 2 (4.0) |
| Family history cancer (n = 47) | |
| No | 33 (70.2) |
| Yes | 14 (29.8) |
| Family history breast/ovarian cancer (n = 47) | |
| No | 42 (89.4) |
| Yes | 5 (10.6) |
| Performance status (n = 45) | |
| 0 | 36 (80) |
| 1 | 6 (13.3) |
| 2 | 3 (6.7) |
| 3 | 0 |
| 4 | 0 |
| Stage at diagnosis | |
| I | 3 |
| II | 7 |
| III | 30 |
| IV | 10 |
| Neoadjuvant treatment (n = 50) | |
| Yes | 14 (20.0) |
| No | 36 (80.0) |
| First-line treatment (n = 50) | |
| Yes | 39 (78.0) |
| No | 11 (22.0) |
| Maintenance treatment (n = 50) | |
| Yes | 33 (66.0) |
| No | 17 (34.0) |
| Response to first-line treatment (n = 39) | |
| Complete response/no evidence of disease | 17 (43.6) |
| Partial response | 12 (30.8) |
| Stable disease | 7 (17.9) |
| Disease progression | 3 (7.7) |
| Maintenance treatment (n = 33) | |
| PARP inhibitor | 9 (27.3) |
| Bevacizumab | 9 (27.3) |
| PARP inhibitor/bevacizumab | 15 (45.4) |
Abbreviations: n: number, PARP: poly(ADP-ribose)-polymerase.